Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: In vitro and in vivo comparison and calculation of in vivo inhibition constants

Clinical Pharmacology and Therapeutics

Volumn 62, Issue 5, 1997, Pages 490-504

  Tran, Agnès ^b   Rey, Elisabeth ^b   Pons, Gérard ^b   Rousseau, Marina ^b   D'Athis, Philippe ^b   Olive, Georges ^b   Mather, Gary G ^b   Bishop, Frances E ^b   Wurden, Colleen J ^b   Labroo, Rita ^b   Trager, William F ^b   Kunze, Kent L ^b   Thummel, Kenneth E ^b   Vincent, Jean C ^b   Gillardin, Jean Marie ^b   Lepage, Francis ^b   Levy, René H ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; 6BETA HYDROXYHYDROCORTISONE; ANTICONVULSIVE AGENT; BUFURALOL; CAFFEINE; CARBAMAZEPINE; CARBON 13; COUMARIN; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; HYDROCORTISONE; MEPHENYTOIN; STIRIPENTOL; WARFARIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; ISOTOPE LABELING; LIVER METABOLISM; METABOLISM; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; CAFFEINE; CARBON DIOXIDE; CARBON ISOTOPES; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DIOXOLANES; EPILEPSY; HUMANS; HYDROCORTISONE; MIXED FUNCTION OXYGENASES; REFERENCE VALUES; TIME FACTORS;

EID: 13144302846     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90044-8     Document Type: Article

References (56)

1. Guidance for industry: drug metabolism/drug interaction studies in the drug development process: studies in vitro. Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research. Edited by the in vitro studies working group of the clinical pharmacology section of the medical policy coordinating committee in the Center for Drug Evaluation and Research, April 1997.
2. Joellenbeck L, Qian Z, Zarba A, Groopman JD. Urinary 6β-hydroxycortisol/cortisol ratios measured by high-performance liquid chromatography for use as a biomarker for the human cytochrome P-450 3A4. Cancer Epidemiol Biomarkers Prev 1992;1:567-72.
3. Kinirons MT, O'Shea D, Downing TE, Fitzwilliam AT, Joellenbeck L, Groopman JD, et al. Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clin Pharmacol Ther 1993;54:621-9.
4. Krivoruk Y, Kinirons MT, Wood AJJ, Wood M. Metabolism of cytochrome P4503A substrates in vivo administered by the same route: lack of correlation between alfentanil clearance and erythromycin breath test. Clin Pharmacol Ther 1994;56:608-14.
5. Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
6. Levy RH, Loiseau P, Guyot M, Blehaut HM, Tor J, Moreland TA. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther 1984;36: 661-9.
7. Loiseau P, Levy RH, Tor J. Two facets of antiepileptic drug interactions as illustrated by stiripentol. In: Pitlick WH, editor. Antiepileptic drug interactions. New York: Demos; 1989. p. 129-42.
8. Rodrigues AD. Use of in vitro human metabolism studies in drug development. Biochem Pharmacol 1994;48:2147-56.
9. Peck CC, Temple R, Collins JM. Understanding consequences of concurrent therapies [editorial]. JAMA 1993;269:1550-2.
10. Butler MA, Land NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP 1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
11. Kotake AN, Schoeller DA, Lambert GH, Baker AL, Schaffer DD, Josephs H. The caffeine CO2 breath test: dose response and route of N-demethylation in smokers and nonsmokers. Clin Pharmacol Ther 1982; 32;261-9.
12. Gorski JC, Jones DR, Wrighton SA, Hall SD. Characterization of dextromethorphan N-demethylation by human liver microsomes. Biochem Pharmacol 1994;48:173-82.
13. Jones DR, Gorski JC, Haehner BD, O'Mara EM Jr, Hall SD. Determination of cytochrome P450 3A4/5 activity in vivo with dextromethorphan N-demethylation. Clin Pharmacol Ther 1996;60:374-84.
14. Ducharme J, Abdullah S, Wainer IW. Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 1996;678:113-28.
15. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
16. Saenger P. 6β-Hydroxycortisol in random urine samples as indicator of enzyme induction. Clin Pharmacol Ther 1983;34:818-21.
17. Kerr BM, Martinez-Lage JM, Viteri C, Tor J, Eddy AC, Levy RH. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia 1991;32:267-74.
18. Farwell J, Anderson GD, Kerr BM, Tor JA, Levy RH. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia 1993;34:305-11.
19. West BD, Preis S, Schroeder CH, Link KP. Studies on the 4-hydroxycoumarins; XVII: the resolution and absolute configuration of warfarin. J Am Chem Soc 1961;83:2676-9.
20. Hermodson MA, Barker WM, Link KP. Studies of the 4-hydroxycoumarins: synthesis of the metabolites and some other derivatives of warfarin. J Med Chem 1971; 14:167-9.
21. Lawrence RF, Rettie AE, Eddy AC, Trager WF. Chemical synthesis, absolute configuration and stereochemistry of formation of 10-hydroxywarfarin: a major oxidative metabolite of (+)-(R)-warfarin from hepatic microsomal preparations. Chirality 1990;2:96-105.
22. Rettie AE, Eddy AC, Heimark LD, Gibaldi M, Trager WF. Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 1989;17:265-70.
23. Wienkers LC, Storch E, Kunze KL, Rettie AE, Trager WF. The formation of (R)-8-hydroxywarfarin in human liver microsomes, a new metabolic marker for the (S)-mephenytoin hydroxylase. Drug Metab Dispos 1996;25:610-4.
24. Kunze KL, Trager WF. Isoform-selective mechanismbased inhibition of human cytochrome P450 CYP1A2 by furafylline. Chem Res Toxicol 1993;6:649-56.
25. Mather GG, Levy RH. Pharmacokinetics of polypharmacy: prediction of drug interactions. In: Leppik IE, editor. Rational polypharmacy. New York: Elsevier; 1996. p. 113-22.
26. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identification of human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990;267:365-71.
27. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)warfarin-drug interactions. Chem Res Toxicol 1992;5:54-9.
28. Weerawarna SA, Geisshulser SM, Jurthy SS, Nelson WL. Enantioselective and diastereoselective hydroxylation of bufuralol: absolute configuration of the 7-(1-hydroxyethyl)-2-[1-hydroxy-2(tert-butylamino) ethyl]benzofurans, the benzylic hydroxylation metabolites. J Med Chem 1991;10:3091-7.
29. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ, Miners JO. Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 1993;46:1975-81.
30. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Droetz DL, Gonzalez FJ, et al. Human liver carbamazepine metabolism: role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47:1969-79.
31. Goldstein JA, Faletto MB, Romkes-Aparks R, Sullivan T, Kirareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
32. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:1-6.
33. Roskos LK. Inhibition of the hepatic metabolism of (S)-propranolol by uremic blood constituents [PhD thesis]. Seattle: University of Washington; 1994, p. 113-86.
34. 13C enrichments in rat breath: non-invasive method for in vivo study of drug enzymatic induction. J Chromatogr 1991;562:341-50.
35. Dumont E, Sclavons M, Desager JP. Use of an internal standard to assay 6β-hydroxy Cortisol in urine. J Liq Chromatogr 1984;7:2051-7.
36. Yue QY, Svensson JO, Sjöqvist F, Säwe J. A comparison of the pharmacokinetics of codeine and its metabolites in healthy Chinese and Caucasian extensive hydroxylators of debrisoquine. Br J Clin Pharmacol 1991;31:643-7.
37. Shaw PN, Houston JB. Kinetics of drug metabolism inhibition: use of metabolic concentration-time profiles. J Pharmacokinet Biopharm 1987;15:497-510.
38. Adedoy A, Aarons LE, Houston JB. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat. Drug Metab Dispos 1987;15:127-32.
39. Kunze KL, Trager WF. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 1996;24:429-35.
40. Kerr BM, Rettie AE, Eddy AC, Loiseau P, Guyot M, Wilensky AJ, et al. Inhibition of human liver microsomal epoxide hydrolase by valproate and valpromide: in vitro/in vivo correlation. Clin Pharmacol Ther 1989;46:82-93.
41. Kroetz DL, Loiseau P, Guyot M, Levy RH. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther 1993;46:485-97.
42. Jacqz-Aigrain E, Menard Y, Popon M, Mathieu H. Dextromethorphan phenotypes determined by high-performance liquid chromatography and fluorescence detection. J Chromatogr 1989;495:361-3.
43. Kerry NL, Somogyi AA, Bochner F, Mikus G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes. J Pharmacol 1994;38: 243-8.
44. Vetticaden SJ, Cabana BE, Prasad VK, Purich ED, Jonkman JH, de Zeeuw R, et al. Phenotypic differences in dextromethorphan metabolism. Pharm Res 1989;6:13-9.
45. 3H-stiripentol chez le rat. Eur J Drug Metab Pharmacokinet 1982;7:5-10.
46. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptakeinhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-83.
47. Hunt CM, Watkins PB, Saenger P, Stave GM, Barlascini N, Watlington CO, et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 1992;51:18-23.
48. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, et al. Comparison of urinary 6β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 1992;52:265-73.
49. Burstein S, Kimball HL, Klaiber EL, Gut M. Metabolism of 2α- and 6β-hydroxycortisol with and without phenobarbital administration. J Clin Endocrinol Metab 1967;27:491-9.
50. Caporaso N, Whitehouse J, Monkman S, Boustead C, Issaq H, Fox S, et al. In vitro but not in vivo inhibition of CYP2D6 by phenethyl isothiocyanate (PEITC), a constituent of watercress. Pharmacogenetics 1994;4: 275-80.
51. Rowland K, Yeo WW, Ellis SW, Chadwick IG, Haq I, Lennard MS, et al. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxypropranolol. Br J Clin Pharmacol 1994;38:9-14.
52. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 175;1991:1112-8.
53. Bajpai M, Roskos LK, Shen DD, Levy RH. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996;24:1401-3.
54. Hargreaves JA, Howald WN, Racha JK, Levy RH. Identification of enzymes responsible for the metabolism of phenobarbital [abstract]. Presented at the seventh North American ISSX Meeting. Bethesda, MD: ISSX, 1996;10:259.
55. Loiseau P, Duché B. Potential antiepileptic drugs: stiripentol. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven; 1995. p. 1045-56.
56. Rowland M, Matin SB. Kinetics of drug-drug interactions. J Pharmacokinet Biopharm 1973;1:553-6.